Excellence is just the beginning.


French German Italian Portuguese Russian

Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype Treatment Study

A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype.

Diffuse Large B-Cell Lymphoma Treatment Study

A phase 2 study of the combination of ublituximab + TGR-1202 and TG-1202 alone in patients with previously treated diffuse large B-cell lymphoma.

Follicular Lymphoma Treatment Study

Study of ibrutinib and rituximab in subjects whose follicular lymphoma has not been treated before.

Mantle Cell Lymphoma Treatment Study

Rituximab with or without stem cell transplant in mantle cell lymphoma.

Marginal Zone Lymphoma Treatment Study

A study of INCB050465 in subjects with relapsed or refractory marginal zone lymphoma.

MYC-Associated B-Cell Lymphomas Treatment Study

Prospective, multi-center phase I/II trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated B-cell lymphomas.

Relapsed or Refractory Follicular Lymphoma Treatment Study

Obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy in treating patients with relapsed or refractory follicular lymphoma.

Relapsed or Refractory Mantle Cell Lymphoma Treatment Study

A phase 2, open-label, 2-cohort, multicenter study of INCB050465, a PI3Kδ inhibitor, in relapsed or refractory mantle cell lymphoma previously treated with or without a BTK inhibitor (CITADEL-205).

Relapsed or Refractory Non-Hodgkin’s B-Cell Lymphoma Treatment Study

Combination gemcitabine and oxaliplatin (GEMOX) therapy with MT-3724 for subjects with relapsed or refractory non-Hodgkin’s B-cell lymphoma.

Treatment Study for Patients with Anaplastic Large Cell Lymphoma

A randomized phase 2 trial of brentuximab vedotin (SGN35, NSC# 749710), or crizotinib (NSC#749005, commercially labeled) in combination with chemotherapy for newly diagnosed patients with anaplastic large cell lymphoma (ALCL) IND#117117.